Literature DB >> 17359407

A combination of total intravenous anesthesia and thoracic epidural for thymectomy in juvenile myasthenia gravis.

Oliver Bagshaw1.   

Abstract

Juvenile myasthenia gravis is the acquired form of the disease in children and presents with ocular signs, fatigability, weakness and bulbar problems. The majority of patients demonstrate thymic hyperplasia and have been shown to benefit from thymectomy. The main considerations for the anesthesiologist are the degree of muscle weakness, the muscle groups involved and sensitivity to neuromuscular blocking drugs and volatile agents. Total intravenous anesthesia (TIVA) with epidural analgesia is probably the anesthetic technique of choice, although the latter is often avoided, because of the risk of a very high block. Two cases of thymectomy are presented where anesthesia was provided using a combination of TIVA and thoracic epidural analgesia. Both patients tolerated the technique well and had an uncomplicated perioperative course.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17359407     DOI: 10.1111/j.1460-9592.2006.02122.x

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  4 in total

1.  Anesthesia for patients undergoing transsternal thymectomy for juvenile myasthenia gravis.

Authors:  Lianne Stephenson; Igor Tkachenko; Robert Shamberger; Christian Seefelder
Journal:  Saudi J Anaesth       Date:  2011-01

2.  Anaesthetic considerations in paediatric myasthenia gravis.

Authors:  Oliver William Masters; Oliver N Bagshaw
Journal:  Autoimmune Dis       Date:  2011-09-25

3.  Management of robotic partial nephrectomy in a patient with myasthenia gravis: General anaesthesia sans neuromuscular blocking agent.

Authors:  Devanahalli Ashokananda; Murali Chakravarthy; Mohan Keshavamurthy
Journal:  Indian J Anaesth       Date:  2022-05-19

4.  Laryngeal mask airway without muscle relaxant in femoral head replacement in elderly patients.

Authors:  Ming Kong; Beiping Li; Yunping Tian
Journal:  Exp Ther Med       Date:  2015-11-09       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.